Vyepti (eptinezumab) is a calcitonin gene-related peptide (CGRP) monoclonal antibody that binds and prevents CGRP from interacting with its receptor, thereby inhibiting neurogenic inflammation and pain signaling associated with cluster headaches. By blocking CGRP, the medication reduces the frequency and severity of cluster headache attacks, providing prophylactic treatment for this severe neurological condition.